© 2016 Elsevier Ireland Ltd. Background and aims: We aimed to assess the prognostic value of free androgen index (FAI) and its change over time in arterial stiffness progression, endothelial function and hypertension in postmenopausal women. Methods: Postmenopausal women (n = 180) without clinically overt cardiovascular disease or diabetes were consecutively recruited and followed for a median of 29 months. The main outcome measures were changes over time in endothelial function (FMD), reflected waves, localized and systemic (PWV) arterial stiffness and hypertension. Results: Increased baseline FAI was significantly associated with new onset hypertension (OR for each SD, 2.71, 95% CI 1.14-6.41, p = 0.024), deterioration of pulse wave velocity (PWV) (0.414 m/s per SD), flow-mediated dilation (FMD) (-0.42% per SD), systolic (2.5 mmHg per SD) and pulse pressure progression (2.3 mmHg per SD, p < 0.05 for all). Baseline FAI remained an independent predictor of changes in PWV (p = 0.006), FMD (p = 0.02), peripheral pulse pressure (p = 0.028), transition to new onset hypertension (p = 0.001) and higher BP category (p = 0.012), after adjustment for age, changes in systolic blood pressure, traditional risk factors, vasoactive medication or total testosterone. Baseline FAI improved reclassification for the risk of transition into higher BP category (NRI = 47.5 ± 20.3%, p = 0.02) and abnormal PWV (NRI = 53.4 ± 23.2%, p = 0.021). Similarly, in a subgroup of patients with measured FAI at follow-up, its changes over time predicted changes in PWV, peripheral pulse pressure and hypertension status (p < 0.05 for all). Conclusions: In apparently healthy postmenopausal women, FAI could be a novel biomarker superior to total testosterone for accelerated vascular aging and hypertension status.

© Athens Medical Society. In March 2013, the Health Procurement Committee of the Greek Ministry of Health appointed a committee consisting of laboratory scientists to compile a list of laboratory tests performed on biological fluids, cells and tissues. This committee compiled a list entitled Catalog of Uniform Nomenclature and Coding of Laboratory Tests (CUNCLT), using as its basis the list of reagents of the European Diagnostics Manufacturers Association (EDMA). The CUNCLT refers to the nomenclature of the laboratory tests and does not include all the materials (reagents, consumables, solutions, calibrators, controls, equipment, etc.) and software that may be necessary for performing the tests. The CUNCLT categorizes the laboratory tests that are performed on biological fluids, cells and tissues into eight main categories, each including subcategories of the 1st and 2nd levels. The eight main categories of the CUNCLT, namely Clinical Chemistry- Biochemistry, Immunochemistry, Hematology, Microbiology (cultures), Infectious Immunology, Molecular Biology and Genetics, Pathology-Cytology, Immunology, generally correspond to the categories of clinical laboratories that operate in public hospitals. The CUNCLT includes a total of 2,403 tests and according to its creation rationale, it is imperative that this list is regularly updated. CUNCLT is an important effort at the recording and classification of the laboratory tests carried out in clinical laboratories on biological fluids, cells and tissues. This list could be the basis for introducing the coding of laboratory tests in the laboratory information systems of public hospitals, for matching with the codes of laboratory tests prescribed by the National Organization for Health Care Services (EOPYY) and for specifications for the purchase of the reagents for laboratory testing.